文献速递间质性肺疾病

住院患者药物性间质性肺病风险:巢式病例对照研究

Risk of drug-induced interstitial lung disease in hospitalised patients: a nested case-control study.
PubMed 文献 · Thorax · 2021-04-22

基于日本全国住院数据库的巢式病例对照研究,纳入住院期间发生药物性间质性肺病(DILD)并需糖皮质激素治疗的患者,按年龄、性别、主诊断、入院年份和医院1:4匹配对照,分析42类216种药物与DILD的关联。结果显示表皮生长因子受体抑制剂(OR 16.84,95%CI 9.32–30.41)和III类抗心律失常药(OR 7.01,95%CI 3.86–12.73)等6类药与DILD风险升高相关,他汀类与风险降低相关(OR 0.68,95%CI 0.50–0.92)。

要点

  • EGFR抑制剂与III类抗心律失常药与DILD风险显著升高相关。
  • 他汀类药物的使用与DILD风险降低相关。
  • 识别高风险药物类别有助于临床预防和早期处理DILD。

核心结论

  • 多种药物类别与住院患者DILD发生存在显著关联,结果可为DILD的预防和治疗提供参考。

研究设计与样本

  • 日本全国住院数据库的巢式病例对照研究,纳入2010年7月至2016年3月入院时无间质性肺炎、住院期间发生DILD并需糖皮质激素治疗的患者,按1:4匹配对照。
  • 回顾性识别2342例DILD患者,匹配后纳入1541例病例和5677例对照,定义42类216种通用名药物为潜在风险药物。
  • 采用条件logistic回归分析各药物类别与DILD发生的关联。

主要发现

  • 共6个药物类别与DILD发生增加显著相关,包括表皮生长因子受体抑制剂(OR 16.84,95%CI 9.32至30.41)。
  • III类抗心律失常药物与DILD风险升高相关(OR 7.01,95%CI 3.86至12.73)。
  • 他汀类药物与DILD风险降低相关(OR 0.68,95%CI 0.50至0.92)。

临床怎么用

  • 对使用EGFR抑制剂或III类抗心律失常药的住院患者,应警惕DILD发生并及时评估糖皮质激素治疗指征。
  • 他汀类与DILD风险降低的关联可作参考,但不能据此推荐用于预防DILD。

局限性

  • 为回顾性数据库研究,DILD识别依赖住院期间需糖皮质激素治疗的定义,可能存在漏诊或错分。
  • 研究基于日本全国住院数据库,结果外推至其他人群需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Information on drug-induced interstitial lung disease (DILD) is limited due to its low incidence. This study investigated the frequencies of drug categories with potential risk in patients developing DILD during hospitalisation and analysed the risk of developing DILD associated with each of these drugs. METHODS: Using a Japanese national inpatient database, we identified patients without interstitial pneumonia on admission who developed DILD and required corticosteroid therapy during hospitalisation from July 2010 to March 2016. We conducted a nested case-control study; four controls from the entire non-DILD patient cohort were matched to each DILD case on age, sex, main diagnosis, admission year and hospital. We defined 42 classified categories of drugs with 216 generic names as drugs with potential risk of DILD, and we identified the use of these drugs during hospitalisation for each patient. We analysed the association between each drug category and DILD development using conditional logistic regression analyses. RESULTS: We retrospectively identified 2342 patients who developed DILD. After one-to-four case-control matching, 1541 case patients were matched with 5677 control patients. Six drug categories were significantly associated with the increased occurrence of DILD. These included epidermal growth factor receptor inhibitors (OR: 16.84, 95% CI 9.32 to 30.41) and class III antiarrhythmic drugs (OR: 7.01, 95% CI 3.86 to 12.73). Statins were associated with reduced risk of DILD (OR: 0.68, 95% CI 0.50 to 0.92). CONCLUSIONS: We demonstrated significant associations between various drug categories and DILD. Our findings provide useful information on drug categories with potential risk to help physicians prevent and treat DILD.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Jo T, Michihata N, Yamana H, et al. Risk of drug-induced interstitial lung disease in hospitalised patients: a nested case-control study. Thorax. 2021. PMID: 33888574. doi:10.1136/thoraxjnl-2020-215824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。